Journal
CLINICAL INFECTIOUS DISEASES
Volume 53, Issue 10, Pages 1019-1023Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir613
Keywords
-
Categories
Funding
- Wellcome Trust, London, United Kingdom [WT081794, WT081667]
- National Institutes of Health [AI014209]
Ask authors/readers for more resources
Background. An inexpensive point-of-care dipstick lateral flow assay for cryptococcal antigen was highly sensitive for detection of cryptococcal antigen in serum, plasma, and urine of cryptococcal meningitis patients and correlated closely with enzyme-linked immunosorbent assay results. Methods. GXM concentrations were determined in paired serum, plasma, and urine from 62 patients with active or recent CM, using a quantitative sandwich enzyme-linked immunosorbent assay (ELISA). A dipstick lateral-flow assay developed using the same monoclonal antibodies for the sandwich ELISA was tested in parallel. Correlation coefficients were calculated using Spearman rank test. Results. All patients had detectable GXM in serum, plasma, and urine using the quantitative ELISA. Comparison of paired serum and plasma showed identical results. There were strong correlations between GXM levels in serum/urine (r(s) = 0.86; P < .001) and plasma/urine (r(s) = 0.85; P < .001). Levels of GXM were 22-fold lower in urine than in serum/plasma. The dipstick test was positive in serum, plasma, and urine in 61 of 62 patients. Dipstick titers correlated strongly with ELISA. Correlations between the methods were 0.93 (P < .001) for serum, 0.94 (P < .001) for plasma, and 0.94 (P < .001) for urine. Conclusions. This novel dipstick test has the potential to markedly improve early diagnosis of CM in many settings, enabling testing of urine in patients presenting to health care facilities in which lumbar puncture, or even blood sampling, is not feasible.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available